Bender Robert & Associates Makes New Investment in Chimerix, Inc. (NASDAQ:CMRX)

Bender Robert & Associates purchased a new position in shares of Chimerix, Inc. (NASDAQ:CMRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,609 shares of the biopharmaceutical company’s stock, valued at approximately $37,000.

Other institutional investors also recently bought and sold shares of the company. Assenagon Asset Management S.A. raised its position in Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after buying an additional 496,823 shares during the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of Chimerix during the 4th quarter valued at approximately $221,000. Valeo Financial Advisors LLC increased its holdings in shares of Chimerix by 78.8% during the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 64,420 shares in the last quarter. Peapod Lane Capital LLC purchased a new position in shares of Chimerix during the 4th quarter valued at approximately $2,626,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares in the last quarter. 45.42% of the stock is owned by hedge funds and other institutional investors.

Chimerix Stock Performance

Chimerix stock opened at $8.45 on Wednesday. The company’s fifty day moving average price is $4.54 and its 200 day moving average price is $2.43. Chimerix, Inc. has a 1 year low of $0.75 and a 1 year high of $8.47. The stock has a market capitalization of $759.96 million, a P/E ratio of -8.99 and a beta of 0.32.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CMRX shares. Jefferies Financial Group reaffirmed a “hold” rating and set a $8.50 target price (down from $10.00) on shares of Chimerix in a report on Wednesday, March 5th. Wedbush reaffirmed a “neutral” rating and set a $8.55 target price (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $8.55 target price (down from $11.00) on shares of Chimerix in a report on Wednesday, March 5th.

Insider Activity at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now owns 609,603 shares of the company’s stock, valued at $2,755,405.56. The trade was a 1.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders have sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is owned by company insiders.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.